Trevor Bushell

Dr. Trevor Bushell

orcid

Research Focus & Metrics

Academic Career Length

32Years (1995-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 November 1998 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
OMOlimpia Meucci
Olimpia Meucci
AFAlessandro Fatatis
Alessandro Fatatis
ASArthur A. Simen
Arthur A. Simen
TBTrevor Bushell
Trevor Bushell
PGPatrick W. Gray
Patrick W. Gray
RMRichard J. Miller
Richard J. Miller
The HIV-1 envelope protein gp120 induces apoptosis in hippocampal neurons. Because chemokine receptors act as cellular receptors for HIV-1, we examined rat hippocampal neurons for the presence of functional chemokine receptors. Fura-2-based Ca imaging showed that numerous chemokines, including SDF-1α, RANTES, and fractalkine, affect neuronal Ca signaling, suggesting that hippocampal neurons possess a wide variety of chemokine receptors. Chemokines also blocked the frequency of spontaneous glutamatergic excitatory postsynaptic currents recorded from these neurons and reduced voltage-dependent Ca currents in the same neurons. Reverse transcription–PCR demonstrated the expression of CCR1, CCR4, CCR5, CCR9/10, CXCR2, CXCR4, and CX 3 CR1, as well as the chemokine fractalkine in these neurons. Both fractalkine and macrophage-derived chemokine (MDC) produced a time-dependent activation of extracellular response kinases (ERK)-1/2, whereas no activation of c-JUN NH 2 -terminal protein kinase (JNK)/stress-activated protein kinase, or p38 was evident. Furthermore, these two chemokines, as well as SDF-1α, activated the Ca- and cAMP-dependent transcription factor CREB. Several chemokines were able also to block gp120-induced apoptosis of hippocampal neurons, both in the presence and absence of the glial feeder layer. These data suggest that chemokine receptors may directly mediate gp120 neurotoxicity.

1 February 2004 in Molecular Pharmacology
Verified
Journal Article
Closed access
PDF file
MGMarco Gruss
Marco Gruss
TBTrevor Bushell
Trevor Bushell
DBDamian P. Bright
Damian P. Bright
WLWilliam R. Lieb
William R. Lieb
AMAlistair Mathie
Alistair Mathie
NFNicholas P. Franks
Nicholas P. Franks
Nitrous oxide, xenon, and cyclopropane are anesthetic gases that have a distinct pharmacological profile. Whereas the molecular basis for their anesthetic actions remains unclear, they behave very differently to most other general anesthetics in that they have little or no effect on GABAA receptors, yet strongly inhibit the N-methyl-d-aspartate subtype of glutamate receptors. Here we show that certain members of the two-pore-domain K+ channel superfamily may represent an important new target for these gaseous anesthetics. TREK-1 is markedly activated by clinically relevant concentrations of nitrous oxide, xenon, and cyclopropane. In contrast, TASK-3, a member of this family that is very sensitive to volatile anesthetics, such as halothane, is insensitive to the anesthetic gases. We demonstrate that the C-terminal cytoplasmic domain is not an absolute requirement for the actions of the gases, although it clearly plays an important modulatory role. Finally, we show that Glu306, an amino acid that has previously been found to be important in the modulation of TREK-1 by arachidonic acid, membrane stretch and internal pH, is critical for the activating effects of the anesthetic gases.

15 November 2001 in Journal of Neuroscience
Verified
Journal Article
Open access
PDF file
GSGilles Sansig
Gilles Sansig
TBTrevor Bushell
Trevor Bushell
VCVernon R. J. Clarke
Vernon R. J. Clarke
ARAndrei Rozov
Andrei Rozov
NBNail Burnashev
Nail Burnashev
HPHerman van der Putten
Herman van der Putten
To study the role of mGlu7 receptors (mGluR7), we used homologous recombination to generate mice lacking this metabotropic receptor subtype (mGluR7−/−). After the serendipitous discovery of a sensory stimulus-evoked epileptic phenotype, we tested two convulsant drugs, pentylenetetrazole (PTZ) and bicuculline. In animals aged 12 weeks and older, subthreshold doses of these drugs induced seizures in mGluR7−/−, but not in mGluR7+/−, mice. PTZ-induced seizures were inhibited by three standard anticonvulsant drugs, but not by the group III selective mGluR agonist (R,S)-4-phosphonophenylglycine (PPG). Consistent with the lack of signs of epileptic activity in the absence of specific stimuli, mGluR7−/−mice showed no major changes in synaptic properties in two slice preparations. However, slightly increased excitability was evident in hippocampal slices. In addition, there was slower recovery from frequency facilitation in cortical slices, suggesting a role for mGluR7 as a frequency-dependent regulator in presynaptic terminals. Our findings suggest that mGluR7 receptors have a unique role in regulating neuronal excitability and that these receptors may be a novel target for the development of anticonvulsant drugs.

1 July 2015 in Human Molecular Genetics
Verified
Journal Article
Open access
PDF file
TSTeresa Sposito
Teresa Sposito
EPElisavet Preza
Elisavet Preza
CMColin J. Mahoney
Colin J. Mahoney
NSNúria Setó-Salvia
Núria Setó-Salvia
NRNatalie S. Ryan
Natalie S. Ryan
SWSelina Wray
Selina Wray
The alternative splicing of the tau gene, MAPT, generates six protein isoforms in the adult human central nervous system (CNS). Tau splicing is developmentally regulated and dysregulated in disease. Mutations in MAPT that alter tau splicing cause frontotemporal dementia (FTD) with tau pathology, providing evidence for a causal link between altered tau splicing and disease. The use of induced pluripotent stem cell (iPSC)-derived neurons has revolutionized the way we model neurological disease in vitro. However, as most tau mutations are located within or around the alternatively spliced exon 10, it is important that iPSC–neurons splice tau appropriately in order to be used as disease models. To address this issue, we analyzed the expression and splicing of tau in iPSC-derived cortical neurons from control patients and FTD patients with the 10 + 16 intronic mutation in MAPT. We show that control neurons only express the fetal tau isoform (0N3R), even at extended time points of 100 days in vitro. Neurons from FTD patients with the 10 + 16 mutation in MAPT express both 0N3R and 0N4R tau isoforms, demonstrating that this mutation overrides the developmental regulation of exon 10 inclusion in our in vitro model. Further, at extended time points of 365 days in vitro, we observe a switch in tau splicing to include six tau isoforms as seen in the adult human CNS. Our results demonstrate the importance of neuronal maturity for use in in vitro modeling and provide a system that will be important for understanding the functional consequences of altered tau splicing.

1 April 1996 in British Journal of Pharmacology
Verified
Journal Article
Open access
PDF file
TBTrevor Bushell
Trevor Bushell
DJDavid E. Jane
David E. Jane
HTHeong‐Wai Tse
Heong‐Wai Tse
JWJeffrey C. Watkins
Jeffrey C. Watkins
JGJohn Garthwaite
John Garthwaite
GCGraham L. Collingridge
Graham L. Collingridge
1 An understanding of the physiological and pathological roles of metabotropic glutamate receptors (mGluRs) is currently hampered by the lack of selective antagonists. Standard extracellular recording techniques were used to investigate the activity of recently reported mGluR antagonists on agonist-induced depressions of synaptic transmission in the lateral perforant path of hippocampal slices obtained from 12–16 day-old rats. 2 The group III specific mGluR agonist, (S)-2-amino-4-phosphonobutanoate (L-AP4) depressed basal synaptic transmission in a reversible and dose-dependent manner. The mean (±s.e.mean) depression obtained with 100 μm L-AP4 (the maximum concentration tested) was 74 ± 3% and the IC50 value was 3 ± 1 μm (n = 5). 3 The selective group II mGluR agonists, (1S,3S)-1-aminocyclopentane-1,3-dicarboxylate ((1S,3S)-ACPD) and (2S,1′R,2′R,3′R)-2-(2′,3′-dicarboxycyclopropyl)glycine (DCG-IV) also depressed basal synaptic transmission in a reversible and dose-dependent manner. The mean depression obtained with 200 μm (1S,3S)-ACPD was 83 ± 8% and the IC50 value was 12 ± 3 μm (n = 5). The mean depression obtained with 1 μm DCG-IV was 73 ± 7% and the IC50 value was 88 ± 15 nM (n = 4). 4 Synaptic depressions induced by the actions of 20 μm (1S,3S)-ACPD and 10 μm L-AP4 were antagonized by the mGluR antagonists, (+)-α-methyl-4-carboxyphenylglycine ((+)-MCPG), (S)-2-methyl-2-amino-4-phosphonobutanoate (MAP4), (2S, 1′S,2′S)-2-methyl-2-(2′-carboxycyclopropyl)glycine (MCCG), (RS)-α-methyl-4-tetrazolylphenylglycine (MTPG), (RS)-α-methyl-4-sulphonophenylglycine (MSPG) and (RS)-α-methyl-4-phosphonophenylglycine (MPPG) (all tested at 500 μm). 5 (+)-MCPG was a weak antagonist of both L-AP4 and (1S,3S)-ACPD-induced depressions. MCCG was selective towards (1S,3S)-ACPD, but analysis of its effects were complicated by apparent partial agonist activity. MAP4 showed good selectivity for L-AP4-induced effects. 6 The most effective antagonist tested against 10 μm L-AP4 was MPPG (mean reversal 90 ± 3%; n = 4). In contrast, the most effective antagonist tested against 20 μm (1S,3S)-ACPD induced depressions was MTPG (mean reversal 64 ± 4%; n = 4). Both antagonists produced parallel shifts in agonist dose-response curves. Schild analysis yielded estimated KD values of 11.7 μm and 27.5 μm, respectively. Neither antagonist had any effect on basal transmission or on depressions induced by the adenosine receptor agonist, 2-chloroadenosine (500 nM; n = 3). 7 We conclude that both group II and group III mGluRs can mediate synaptic depressions induced by mGluR agonists in the lateral perforant path. The mGluR antagonists MTPG, MPPG and MAP4 should be useful in determining the roles of group II and III mGluRs in the central nervous system.

1 April 2001 in The FASEB Journal
Verified
Journal Article
Closed access
Jeremy MarksJeremy Marks
Jeremy Marks
Chien-Yuan PanChien-Yuan Pan
Chien-Yuan Pan
TBTrevor Bushell
Trevor Bushell
WCWilliam Cromie
William Cromie
RLRaphael C. Lee
Raphael C. Lee